Literature DB >> 21506636

TLR-7 and -8 agonists as vaccine adjuvants.

Mark A Tomai, John P Vasilakos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21506636     DOI： 10.1586/erv.11.26

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN： 1476-0584            Impact factor:   5.217


× No keyword cloud information.
  14 in total

1.  Distinct TLR adjuvants differentially stimulate systemic and local innate immune responses in nonhuman primates.

Authors:  Marcin Kwissa; Helder I Nakaya; Herold Oluoch; Bali Pulendran
Journal:  Blood       Date:  2012-01-12       Impact factor: 22.113

Review 2.  Adjuvants for human vaccines.

Authors:  Carl R Alving; Kristina K Peachman; Mangala Rao; Steven G Reed
Journal:  Curr Opin Immunol       Date:  2012-04-19       Impact factor: 7.486

3.  Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1-dependent pathways.

Authors:  Victoria J Philbin; David J Dowling; Leighanne C Gallington; Guadalupe Cortés; Zhen Tan; Eugénie E Suter; Kevin W Chi; Ariel Shuckett; Liat Stoler-Barak; Mark Tomai; Richard L Miller; Keith Mansfield; Ofer Levy
Journal:  J Allergy Clin Immunol       Date:  2012-04-21       Impact factor: 10.793

4.  Innate Immune Responses and P. falciparum CS Repeat-Specific Neutralizing Antibodies Following Vaccination by Skin Scarification.

Authors:  Robert A Mitchell; Rita Altszuler; Sandra Gonzalez; Roshawn Johnson; Ute Frevert; Elizabeth Nardin
Journal:  Front Immunol       Date:  2022-06-06       Impact factor: 8.786

5.  Injectable, Ribbon-Like Microconfetti Biopolymer Platform for Vaccine Applications.

Authors:  Kathryn M Moore; Cole J Batty; Rebeca T Stiepel; Christopher J Genito; Eric M Bachelder; Kristy M Ainslie
Journal:  ACS Appl Mater Interfaces       Date:  2020-08-24       Impact factor: 9.229

Review 6.  Polyphosphazene immunoadjuvants: Historical perspective and recent advances.

Authors:  Alexander K Andrianov; Robert Langer
Journal:  J Control Release       Date:  2020-12-05       Impact factor: 9.776

7.  Resiquimod and polyinosinic-polycytidylic acid formulation with aluminum hydroxide as an adjuvant for foot-and-mouth disease vaccine.

Authors:  Chun-Xue Zhou; Dong Li; Ying-Li Chen; Zeng-Jun Lu; Pu Sun; Yi-Mei Cao; Hui-Fang Bao; Yuan-Fang Fu; Ping-Hua Li; Xing-Wen Bai; Bao-Xia Xie; Zai-Xin Liu
Journal:  BMC Vet Res       Date:  2014-01-03       Impact factor: 2.741

8.  Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release.

Authors:  Petr O Ilyinskii; Christopher J Roy; Conlin P O'Neil; Erica A Browning; Lynnelle A Pittet; David H Altreuter; Frank Alexis; Elena Tonti; Jinjun Shi; Pamela A Basto; Matteo Iannacone; Aleksandar F Radovic-Moreno; Robert S Langer; Omid C Farokhzad; Ulrich H von Andrian; Lloyd P M Johnston; Takashi Kei Kishimoto
Journal:  Vaccine       Date:  2014-03-01       Impact factor: 3.641

Review 9.  Immunopotentiating and Delivery Systems for HCV Vaccines.

Authors:  Alexander K Andrianov; Thomas R Fuerst
Journal:  Viruses       Date:  2021-05-25       Impact factor: 5.048

10.  The ultra-potent and selective TLR8 agonist VTX-294 activates human newborn and adult leukocytes.

Authors:  David J Dowling; Zhen Tan; Zofia M Prokopowicz; Christine D Palmer; Maura-Ann H Matthews; Gregory N Dietsch; Robert M Hershberg; Ofer Levy
Journal:  PLoS One       Date:  2013-03-04       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.